ONCAlert | 2018 ASCO Annual Meeting
Colorectal Cancer Case Studies

Cathy Eng, MD, FACP: Continuation of Anti-Angiogenesis Therapy

Cathy Eng, MD, FACP
Published Online:Aug 12, 2015
Diane B. is a 72-year-old retired elementary school teacher from Chicago, Illinois.

Metastatic Colorectal Cancer: Part 1

Metastatic Colorectal Cancer: Part 1
Metastatic Colorectal Cancer: Part 2
Metastatic Colorectal Cancer: Part 1
Metastatic Colorectal Cancer: Part 2
Metastatic Colorectal Cancer: Part 1
Metastatic Colorectal Cancer: Part 2


Should anti-angiogenesis therapy be continued in this patient?

Cathy Eng, MD, FACP, The University of Texas MD Anderson Cancer Center, says anti-angiogenic therapy could definitely be continued in this patient. It’s been demonstrated in prior studies that continuing beyond progression from first-line therapy does benefit patients in regards to the continuation of anti-angiogenic therapy, in combination with chemotherapy. Bevacizumab could be continued. Other antiangiogenic agents could be considered as well, such as ramucirumab and ziv-aflibercept, in combination with irinotecan-based therapy

CASE: Metastatic Colorectal Cancer (Part 1)

Diane B. is a 72-year-old retired elementary school teacher from Chicago, Illinois.
  • Her prior medical history is notable for stage I cervical cancer at age 20 years, treated with cobalt therapy and total hysterectomy
The patient was diagnosed with metastatic colorectal cancer in January of 2013, after presenting to her PCP with progressive fatigue of 3 month’s duration and irregular bowel movements; Patient’s performance status was 1.
  • CT scan revealed a large nonobstructive mass in the sigmoid colon with multiple large hepatic lesions; the patient’s CEA level was 158 ng/mL
  • Patient was not indicated for surgery due to minimal symptoms and presence of metastatic disease
  • Biopsy of the sigmoid mass and hepatic lesion showed adenocarcinoma, and mutational testing showed KRAS WT; BRAF negative; RAS status was not determined
  • Diane underwent initial therapy for metastatic disease with FOLFOX + bevacizumab
  • Following 6 cycles, patient had a response with a decrease in several stable hepatic lesions the primary mass on CT; her CEA decreased to 25 ng/mL
  • At 4 months, the patient had developed sensory neuropathy (grade 2), and oxaliplatin was discontinued from her regimen; 5-FU, leucovorin, and bevacizumab were continued
In January of 2014, she presented to her oncologist for evaluation after her CEA had increased to 77 ng/mL.
  • The patient was asymptomatic at the time of recurrence, and her neuropathy had improved to grade 1
Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.